Antineoplastics: Lack of efficacy.

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 52-year-old man exhibited lack of efficacy during treatment with gemcitabine, paclitaxel, demcizumab, entrectinib, brigatinib, lorlatinib, capecitabine, oxaliplatin, pembrolizumab, trastuzumab, pemetrexed, pertuzumab, bevacizumab, docetaxel, osimertinib and trastuzumab-deruxtecan for metastatic pancreatic cancer [dosages and routes not stated]. [Extracted from the article]